October 4, 2024Open Access
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Key Points
Key points are not available for this paper at this time.
Abstract
Nct02477826, Nct03215706.